Amicus Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

CRANBURY, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Tuesday, October 2, 2018 at 1:00 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at, and will be archived for 90 days.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.  With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at

Amicus Therapeutics
Andrew Faughnan
Associate Director, Investor Relations
(609) 662-3809

Media / Multimedia Assets:
Pure Communications
Jennifer Paganelli
(347) 658-8290



Source: Amicus Therapeutics, Inc.